Pharmacokinetic properties of several novel oligonucleotide analogs in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 2, 1996, Pages 923-937

  Crooke, Stanley T ^a   Graham, Mark J ^a   Zuckerman, Joan E ^a   Brooks, Douglas ^a,b   Conklin, Boyd S ^a   Cummins, Lendell L ^a   Greig, Michael J ^a   Guinosso, Charles J ^a   Kornbrust, Douglas ^c   Manoharan, Muthiah ^a   Sasmor, Henri M ^a   Schleich, Thomas ^b   Tivel, Kathleen L ^a   Griffey, Richard H ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; ISIS 3082; ISIS 8005; ISIS 9044; ISIS 9045; ISIS 9046; ISIS 9047; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; KIDNEY METABOLISM; LIVER METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BASE SEQUENCE; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; LIVER; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BINDING; THIONUCLEOTIDES; TISSUE DISTRIBUTION;

EID: 12644302203     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. AGRAWAL, S., TEMSAMANI, J. AND TANG, J. Y.: Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. U.S.A. 88: 7595-7599, 1991.
2. AGRAWAL, S., ZHANG, X., LU, Z., ZHAO, H., TAMBURIN, J. M., YAN, J., CAI, H., DIASIO, R. B., HABUS, I , JIANG, Z , IYER, R. P., YU, D. AND ZHANG, R.: Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 30: 571-576, 1995.
3. BEAUCAGE, S. L. AND IYER, R. P.: Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48: 2223-2311, 1992.
4. BENNETT, C. F. AND CROOKE, S. T.: Regulation of endothelial cell adhesion molecule expression with antisense oligonucleotides. In Advances in Pharmacology, Vol. 28, ed. by J. T. August, M. W. Anders, F. Murad and J. T. Coyle, p. 1, Academic Press, New York, 1994.
5. CAMPBELL, J. M., BACON, T. A. AND WICKSTROM, E.: Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophy. Methods 20: 259-267, 1990.
6. COOK, P. D.: Medicinal chemistry strategies for antisense research. In Antisense Research and Applications, ed. by S. T. Crooke and B. Lebleu, p. 149, CRC Press, Inc., Boca Raton, 1993.
7. CORNISH, K G., IVERSEN, P., SMITH, L., ARNESON, M. AND BAYEVER, E.: Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol. Commun. 3: 239-247, 1993.
8. COSSUM, P. A., SASMOR, H., DELLINGER, D., TRUONG, L., CUMMINS, L., OWENS, S. R., MANKHAM, P. N., SHEA, J. P. AND CROOKE, S. T.: Disposition of the 14C-labeled phosphorothioate oligonucleotide Isis 2105 after intradermal administration to rats. J. Pharmacol. Exp. Ther. 267: 1181-1190, 1993.
9. COSSUM, P. A., TRUONG, L., OWENS, S. R., MARKHAM, P. N., SHEA, J. P. AND CROOKE, S. T.: Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide Isis 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267: 89-94, 1994.
10. CROOSE, R. M.: In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-Cancer Drug Design 6: 609-646, 1991.
11. CROOKE, R. M.: In vitro and in vivo toxicology of first generation analogs. In Antisense Research and Applications, ed. by S. T. Crooke and B. Lebleu, p. 427, CRC Press, Boca Raton, 1993.
12. CROOKE, S. T.: Therapeutic Applications of Oligonucleotides, R G. Landes Co., Austin, 1995a.
13. CROOKE, S. T.: Oligonucleotide therapeutics. In Burger's Medicinal Chemistry and Drug Discovery, Vol. 1, ed. by M. E. Wolff, p. 863, J. Wiley and Sons, New York, 1995b.
14. CROOKE, R. M., GRAHAM, M. J., COOKE, M. E. AND CROOKE, S. T.: In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J. Pharmacol. Exp. Ther. 275: 462-673, 1995.
15. CROOKE, S. T., GRILLONE, L. R., TENDOLKAR, A., GARRETT, A., FRATKIN, N. J., LEEDS, J. AND BARr, W. H.: A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in genital wart patients. J. Pharmacol. Exp. Ther. 56: 641-646, 1994.
16. CUMMINS, L. L., OWENS, S. R., RISEN, L. N., LESNIK, E. A., FREIER, S. N., MCGEE, D., GUINOSSO, C. J., COOK, P. D.: Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res. 23: 2019-2024, 1995.
17. DE SMIDT, P. C., LE DOAN, T., DE FALCO, S. AND VAN BERKEL, T. J. C.: Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res. 19: 4695-4700, 1991.
18. FREIER, S. M., ALBERGO, D. D. AND TURNER, D. H.: Solvent effects on the dynamics of (dG-dC)3. Biopolymers 22: 1107-1131, 1983.
19. GAO, W. Y., HAN, F.-S., STORM, C., EGAN, W., CHENG, Y-C.: Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Mol Pharmacol. 41: 223-229, 1991.
20. GALBRAITH, W. M., HOBSON, W. C., GICLAS, P. C., SCHECHTER, P. J. AND AGRAWAL, S.: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Devel. 4: 201-207, 1994.
21. GRAHAM, M. J., FREIER, S. M., CROOKE, R. M., ECKER, D. J., MASLOVA, R. N. AND LESNIK, E. A.: Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res. 21: 3737-3743, 1993.
22. GREIG, M. J., GAUS, H. J., CUMMINS, L. L., SASMOR, H. AND GRIFFEY, R. H.: Measurement of macromolecular binding using electrospray mass spectrometry. Determination of dissociation constants for oligonucleotide:serum albumin complexes. J. Am. Chem. Soc. 117: 10765-10766, 1995.
23. GREIG, M. J AND GRIFFEY, R. H.: Utility of organic bases for improved electrospray mass spectroscopy of oligonucleotides. Rapid Commun. Mass Spectromet. 9: 97-102, 1995.
24. HANER, R. L. AND SCHLIECH, T.: Measurement of translational motion by pulse-gradient spin-echo nuclear magnetic resonance. Methods Enzyme 176: 418-446, 1989.
25. HOKE, G. D., DRAPER, K., FREIER, S. M., GONZALEZ, C., DRIVER, V. B., ZOUNES, M. C. AND ECKER, D. J.: Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res. 19: 5743-5748, 1991.
26. IVERSEN, P.: In vivo studies with phosphorothioate oligonucleotides: Pharmacokinetic prologue. Anti-Cancer Drug Design 6: 531-538, 1991.
27. KRIEG, A. M., TONKINSON, J., MATSON, S., ZHAO, Q., SAXON, M., ZHANG, L.-M., BHANJA, U., YAKUBOV, L. AND STEIN, C. A.: Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesterol moiety increases cellular association and improves efficacy. Proc. Natl. Acad. Sci. U.S.A. 90: 1048-1052, 1993.
28. MANOHARAN, M., TIVEL, K. L., ANDRADE, L. K. AND COOK, P. D.: 2′-O- and 3′-O-pyrimidine aminotether-containing oligonucleotides: Synthesis and conjugation chemistry. Tetrahedron Lett. 36: 3647-3650, 1995a.
29. MANOHARAN, M., TIVEL, K. L. AND COOK, P. D.: Lipidic nucleic acids. Tetrahedron Lett. 36: 3651-3654, 1995b.
30. MONIA, B. P., JOHNSTON, J. F., ECKER, D. J., ZOUNES, M. A., LIMA, W. F. AND FREIER, S. M.: Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem 267: 19954-19962, 1992.
31. NECKERS, L. M.: Cellular internalization of oligodeoxynucleotides. In Antisense Research and Applications, ed. by S. T. Crooke and B. Lebleu, p. 451, CRC Press, Boca Raton, 1993.
32. 65 binding mode. Cation and anion effects and polynucleotide specificity. Biochemistry 27: 456-471, 1988.
33. PISETSKY, D. S. AND REICH, C. F.: Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 54: 101-107, 1993.
34. RAPPOPORT, J., HANS, B., KOPP, J. B., COPELAND, T. D., BRUGGEMAN, L. A., COFFMAN, T. M. AND KLOTMAN, P E.: Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy. Kidney Int. 47: 1462-1469, 1995.
35. SANDS, H., GOREY-FERET, L. J., COCUZZA, A. J., HOBBS, F. W., CHIDESTER, D., AND TRAINOR, G. L.: Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I.: Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45: 932-943, 1994.
36. SANGHVI, Y. S. AND COOK, P. D.: Towards second-generation synthetic backbones for antisense oligonucleosides. In Nucleosides and Nucleotides as Antitumor and Antiviral Agents, ed. by C. K. Chu and D. C. Baker, p. 311-324, Plenum Press, New York, 1993.
37. STEIN, C. A. AND CHENG, Y.-C.: Antisense oligonucleotides as therapeutic agents - Is the bullet really magic? Science (Wash. DC) 261: 1004-1012, 1993.
38. STEPKOWSKI, S. M., TU, Y., CONDON, T. P. AND BENNETT, C. F.: Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol. 10: 5336-5346, 1994.
39. WAGNER, R. W.: Gene inhibition using antisense oligodeoxynucleotides. Nature (Lond.) 372: 333-335, 1994.
40. WICKSTROM, E.: Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem. Biophys. Methods 13: 97-102, 1986.
41. ZHANG, R., LU, Z., ZHAO, H., ZHANG, X., DIASIO, R.., HABUS, I., HIANG, Z., IYER, R. P., YU, D. AND AGRAWAL, S.: In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. 30: 545-556, 1995.